Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp rug-eluting stents (DES) have drastically reduced in-stent late loss (LL) and target lesion revascularization (TLR) by inhibiting neointimal hyperplasia. 1,2 However, poor reendothelialization, partly due to hypersensitivity reactions to polymer carriers, has gained attention as a cause for late stent thrombosis (LST) with first-generation DES. 3-5With the second-generation DES, various attempts have been made to achieve both inhibitory effects on restenosis and sufficient arterial repair. The TRE-956 stent (Terumo Corporation, Tokyo, Japan) is a second-generation DES that elutes biolimus A9, an analog of sirolimus. Because biolimus A9 is more highly lipophilic than sirolimus, the transport and tissue retention of the drug should be better. 6,7 Biodegradable polymer (polylactic acid) is adopted only to the abluminal stent surface, ensuring that drug is distributed to the target vessel tissue side. Hence, adequate vascular healing as well as strong inhibitory effects on restenosis may be expected with the TRE-956 stent. Using angioscopy, we sought to investigate the intra-stent conditions following biolimus A9-eluting stent (BES) implantation, and to compare the results with the first-generation sirolimus-eluting stents (SES, Cypher, Cordis, Miami Lakes, FL, USA).
Methods
PatientsThe study subjects consisted of 31 DES implanted in 24 patients (19 men, age range 50-80 years) who suffered from stable angina pectoris. Background: Second-generation drug-eluting stents (DES) are expected to show better arterial repair than older DES. We angioscopically compared the biodegradable polymer-coated biolimus A9-eluting stent (BES) and durable polymer-coated sirolimus-eluting stent (SES) to explore differences in arterial repair.